Loading...
Publication
Maternal and perinatal outcomes in pregnant women with rheumatic diseases treated with biosimilar TNF inhibitors
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 513.99 KB | Adobe PDF |
Advisor(s)
Abstract(s)
No safety or efficacy issues arose from using biosimilar TNFi during conception or pregnancy.
Description
Keywords
Pregnancy Rheumatic disorders Mothers Perinatal period Tumor necrosis factor inhibitors Biosimilar pharmaceuticals
